Perspectives on the in vitro evaluation of anti‐anaphylactic agents

Abstract

Weinryb, I., S.M. Coutts, and A.S. Khandwala: Perspectives on the in vitro evaluation of anti-anaphylactic agents. Drug Dev. Res. 3213-219, 1983. In vitro models of anaphylaxis such as the release of mediators from the mast cell can do more than identify compounds with intrinsic anti-allergic activity; they have the potential for development of a detailed profile of activity that may be compared and contrasted in several ways to that of disodium cromoglycate. These parameters include effects upon a) immunologic versus nonimmunologic release, b) IgE-versus IgG-provoked release, c) timing of compound addition relative to challenge, d) repeated administration (presence or absence of tachyphylaxis), e) wash-out of agent (reversibility), and 9 other granulocyte models relative to the mast cell. Use of in vitro models of anaphylaxis in this way allows an early judgment to be made about the extent to which a new compound presents a novel anti-allergic profile.

Antiallergic Activity Profiles in vitro of RHC 3164 and Related Compounds

“…Sensitized rat peritoneal mast cells, human baso phils and guinea pig lung slices are useful in vitro models for identifying new antiallergic agents and for comparing their activity profiles with that of DSCG [17]. In a previous communication a new series of an tiallergic agents were profiled in the above-mentioned in vitro models of anaphylaxis and in general were found to exhibit activity profiles similar to that of DSCG in that: (a) they were potent inhibitors of IgEmediated release of histamine from rat mast cells but not human basophils; (b) they had little or no effect on IgG i-mediated release of histamine from guinea pig lung slices, and (c) in the RMC model they were effective only when added simultaneously with anti gen but not if preincubated with RMC for 5 min prior to the addition of antigen [13].…”